Similarly, the RAF/MEK treatment affects BRAF wild type melanoma cells and fibroblasts similarly by killing cells only at high concentration, suggesting that the non-targeted effect of the MEK inhibitor Trametinib kills cells indiscriminately and mainly at higher concentrations. This evidence concerns the gene MAP2K7 and melanoma.